
Please try another search
Lexaria Bioscience Corp. operates as a biotechnology company. It offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods. The company’s DehydraTECH is used with a range of active molecules, including glucagon-like peptide-1 drugs (GLP-1) and glucose -dependent insulinotropic polypeptide drugs (GIP), vitamins, pain medications, hormones, phosphodiesterase type 5 (PDE5) inhibitors, antivirals, nicotine and its analogs, and cannabinoids. Its DehydraTECH technology is applied to various therapeutic indications, such as diabetes, weight loss, hypertension, and heart disease; is implemented in a multitude of ingestible or topically administered product formats comprising oral suspensions, tablets, capsules, foods, beverages, creams, lotions, and skin patches; and is suitable for a variety of product formats, including pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The company was formerly known as Lexaria Corp. and changed its name to Lexaria Bioscience Corp. in April 2016. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
Name | Age | Since | Title |
---|---|---|---|
Nicholas W. Baxter | 71 | 2011 | Independent Director |
William Edward McKechnie | 78 | 2015 | Independent Director |
Philip N. Ainslie | - | 2024 | Member of Scientific Advisory Board, Advisor & Consultant |
Baljinder Kaur Bhullar | 55 | 2009 | Director |
Albert L. Reese | 75 | 2021 | Independent Director |
John M. Docherty | 56 | 2015 | Chairman of the Scientific Advisory Board, Chief Scientific Officer, President & Director |
Richard C. Christopher | 55 | 2024 | CEO & Director |
C. Michael Gibson | - | 2024 | Chief Medical Advisor & Member of Scientific Advisory Board |
Karen Aust | - | 2024 | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review